Reimbursed Care Access in New Caledonia

Currently classified as a strictly controlled substance under French drug‑scheduling (listed among 'stupéfiants') with no authorised medical use in routine care outside approved clinical research or exceptional import authorisations; therefore in New Caledonia there is no routine medical prescribing or reimbursement for psilocybin outside authorised clinical trials or specific import/compassionate procedures. # #

Currently classified as a strictly controlled substance under national drug scheduling laws and treated as a 'stupéfiant' in French law; there is no authorised medical/ reimbursed MDMA therapy available in routine care in New Caledonia outside approved clinical research. # #

Esketamine nasal spray (Spravato) holds a European marketing authorisation for treatment‑resistant major depressive disorder and is regulated as a hospital‑only medicine in France; access in New Caledonia would follow the territory's hospital/medicine import and authorisation procedures and align with French/European regulatory status, but local reimbursement and availability depend on New Caledonia's hospital formulary decisions and any metropolitan France reimbursement arrangements extended to the territory. The European Medicines Agency granted marketing authorisation for SPRAVATO on 18 December 2019 (EMA decision). # In France SPRAVATO is distributed and used under hospital restrictions and has been listed and described in national drug compendia (Vidal, HAS listings for hospital medicines), with supervised administration requirements due to safety/REMS‑like controls. # #. Practical notes: Spravato administration is restricted to supervised clinic/hospital settings because of acute blood‑pressure and dissociation risks; where it is available in New Caledonia it would typically be hospital‑administered and subject to local procurement and billing rules (possible reimbursement only if local social‑security arrangements or hospital tariffs cover it).

Ketamine is a controlled medicine in France (classed among substances regulated as stupéfiants for many uses) but remains an established, licit anaesthetic and analgesic in hospital practice; it is subject to secure‑prescription/traceability rules and reserved principally to hospital use. Off‑label intravenous or subanaesthetic ketamine for psychiatric indications (e.g., treatment‑resistant depression) is practiced in some clinical settings but is not a nationally standard reimbursed indication in France and therefore in New Caledonia such use would be off‑label, clinician‑directed, and subject to local hospital policy and billing (i.e., typically not routinely reimbursed as an established labelled psychiatric treatment). # # #

Currently classified as a strictly controlled psychotropic/stupéfiant under French scheduling with no authorised medical use in routine care outside approved clinical research; consequently there is no authorised medical prescribing or reimbursement for DMT in New Caledonia. # #

Currently classified as a strictly controlled substance under French drug scheduling with no authorised medical use outside approved clinical research; therefore no routine medical access or reimbursement in New Caledonia. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws with no authorised medical use in routine care in France and thus no authorised/reimbursed access in New Caledonia outside tightly regulated clinical research or exceptional import authorisations. # #

Brew preparations containing DMT (ayahuasca) are effectively prohibited because DMT is a scheduled/stupéfiant substance under French law; there is no authorised medical use or routine reimbursement in New Caledonia outside approved clinical research or tightly‑controlled religious exemptions (which are not a general medical pathway). # #

Mescaline is listed among controlled 'stupéfiants' under French schedules and therefore has no authorised medical/reimbursed use in routine care in New Caledonia outside approved clinical trials or explicit exceptional authorisations. #

Compounds in the 2C family and numerous 2C derivatives are included on the French controlled substances lists (annexed/decreed additions) and are treated as illicit psychotropic/stupefiant substances; there is no authorised medical use or reimbursement for 2C‑class drugs in New Caledonia outside approved clinical research. Standardized policy: 'Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.' #